A Growing Breast Mass in a 34-Year-Old
A 34-year-old woman notices a firm, 2.5 cm mass in the upper outer quadrant of her right breast that has enlarged over 6 weeks. No nipple discharge, no skin changes. She is otherwise healthy, has no family history of breast or ovarian cancer, and is not pregnant. Examination: mobile, well-circumscribed, nontender mass without overlying skin or chest wall fixation; no axillary lymphadenopathy. Diagnostic mammography is dense but shows a circumscribed mass without suspicious calcifications; targeted ultrasound shows a solid, hypoechoic, well-circumscribed mass with posterior enhancement, 2.6 cm, classified BI-RADS 4A. Core needle biopsy is recommended. She asks why she cannot simply have it removed, and whether she needs genetic testing.
1. Justify the biopsy-first strategy over excisional biopsy, and explain what BI-RADS 4A implies.
Read the worked answer
Biopsy first, operate later. A core needle biopsy establishes histology before committing to an operation, which changes the plan:
- If fibroadenoma (most likely in this age group for a circumscribed, mobile mass): excision may be avoided or deferred; observation is acceptable for a biopsy-proven fibroadenoma that is stable and not enlarging rapidly.
- If malignant (e.g., medullary, mucinous, or a well-circumscribed carcinoma): the patient needs staging, receptor status, and a plan that may include neoadjuvant therapy or breast-conserving surgery with margins-an initial excisional biopsy could compromise oncologic planning and cosmesis.
- If phyllodes tumor: requires excision with margins; biopsy helps anticipate this and avoid an inadequate "shell-out."
BI-RADS 4A means low suspicion for malignancy (~2–10%) but biopsy is warranted. It is not a diagnosis and does not justify skipping tissue sampling; conversely, it does not mandate mastectomy or axillary surgery.
Practical point: A 2.6 cm mass that is enlarging over 6 weeks is not simply "leave it alone"-tissue diagnosis is the correct next step.
2. Does this patient meet criteria for hereditary breast cancer genetic testing? Explain your reasoning.
Read the worked answer
Based on the information given, she does not clearly meet testing criteria-but the answer depends on the biopsy result, so testing is not simply "no."
Standard referral triggers include: breast cancer diagnosed at a young age (commonly ≤45, or ≤50 with additional features), triple-negative breast cancer at ≤60, male breast cancer, ovarian/pancreatic/prostate cancer in the family, two or more close relatives with breast cancer, Ashkenazi Jewish ancestry, or a known familial mutation. She has none of these at present: age 34 without cancer diagnosis, no family history, no ancestry information given.
However: if the biopsy returns breast cancer, her age alone (≤45 at diagnosis) generally meets criteria for genetic evaluation, and testing (e.g., BRCA1/2 and a multigene panel) should be offered, with implications for surgical choice (contralateral risk, mastectomy decisions) and family screening.
If the biopsy is benign, routine genetic testing is not indicated; address modifiable risk and screening per population guidelines.
3. The biopsy returns a fibroadenoma. How do you counsel her about management, and what would change your recommendation?
Read the worked answer
Counseling for biopsy-proven fibroadenoma:
- Reassure: fibroadenomas are benign and carry a very small absolute risk of harboring or preceding malignancy.
- Observation is reasonable: clinical follow-up and imaging (ultrasound) at roughly 6 months to confirm stability, then per age-appropriate screening. Excision is not mandatory.
- Excision is reasonable if: the patient prefers removal, the mass continues to enlarge, symptoms are bothersome, or imaging/histology are discordant.
What would change the plan:
- Rapid continued growth or new suspicious imaging features → re-biopsy or excision (consider phyllodes tumor, which can be underdiagnosed on core biopsy).
- Histologic discordance (e.g., atypical ductal hyperplasia, lobular neoplasia, or any atypia on core) → excisional biopsy to exclude upgrade.
- Patient preference or inability to comply with follow-up.
Avoid overpromising: "benign" on core is highly reassuring but not a guarantee; document the plan for interval imaging.